-
Mashup Score: 0
The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
The FDA issued complete response letters (CRLs) for the biologics license application for #odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (#DLBCL). Read more: https://t.co/8nKulfr3kG